Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.

Overview

The purpose of this study is to determine the true incidence of long QT (LQT) amongst a large cohort of subjects diagnosed with unilateral (right/left) or bilateral sensorineural hearing loss.

Full Title of Study: “Long QT & Hearing Loss Prospective Study Registry”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 18, 2020

Detailed Description

The purpose of this study is to determine the true incidence of long QT (LQT) amongst a large cohort of subjects diagnosed with unilateral (right/left) or bilateral sensorineural hearing loss. The goal of this study is to answer the following questions: 1. What is the incidence of an abnormal ECG (QTc > 450 msec) in neonates greater than a week of age with either unilateral or bilateral Sensorineural hearing loss? 2. What percentage of neonates greater than one week of age with either bilateral or unilateral sensorineural hearing loss and an abnormal ECG have an identifiable genetic mutation? 3. What is the incidence of an abnormal genetic mutation consistent with long QT regardless of the ECG in neonates with bilateral sensorineural hearing loss?

Clinical Trial Outcome Measures

Primary Measures

  • The incidence of an abnormal ECG (QTc > 450) in neonates greater than a week of age with either unilateral or bilateral sensorineural hearing loss
    • Time Frame: 6 months
    • ECG results to determine QTc length

Secondary Measures

  • In neonates > 1 week of age with either bilateral or unilateral sensorineural hearing loss and an abnormal ECG, percentage have an identifiable genetic mutation
    • Time Frame: One year
    • Audiology diagnostic results

Participating in This Clinical Trial

Inclusion Criteria

  • All newborns who demonstrate a refer in one or both ears on a routine newborn hearing screen – Documentation of informed consent – Inborn – Ability to perform an ABR (auditory brainstem response screen technology) screening test – No major anomalies – Subjects' parents willing to provide follow-up data on their child Exclusion Criteria:

  • Newborns with a syndromic cause of hearing loss – Parents unwilling to provide follow-up data – Major congenital anomalies – Major medical problem or conditions. (i.e., hypoxic ischemic encephalopathy (HIE), persistent pulmonary hypertension neonate (PPHN), meconium aspiration, etc.) – Congenital cytomegalovirus (CMV)

Gender Eligibility: All

Minimum Age: 1 Day

Maximum Age: 90 Days

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Pediatrix
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mitchell Cohen, MD, Principal Investigator, Pediatrix

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.